This clinical trial is focused on studying the long-term safety and tolerability of a treatment called ianalumab in patients with Systemic Lupus Erythematosus (SLE). SLE is a chronic autoimmune disease where the body’s immune system mistakenly attacks healthy tissue, causing inflammation and damage to various parts of the body. The study involves administering ianalumab, which is given as a solution for injection under the skin, either monthly or quarterly. The purpose of the study is to evaluate how safe and well-tolerated ianalumab is over an extended period.

Participants in the study may receive ianalumab or a placebo. The study will monitor participants for any side effects or adverse reactions that may occur during the treatment period. The study will also assess the overall health and condition of the participants over time, including any changes in their disease symptoms and the use of other medications, such as oral corticosteroids, which are often used to reduce inflammation in SLE.

The study is designed to last for several years, allowing researchers to gather comprehensive data on the long-term effects of ianalumab in treating SLE. Participants will be regularly evaluated to track their progress and any changes in their condition. This research aims to provide valuable insights into the potential benefits and risks of using ianalumab as a treatment option for individuals living with Systemic Lupus Erythematosus.